Emerging drugs for chronic lymphocytic leukaemia

Expert Opinion on Emerging Drugs
Karen W L Yee, S M O'Brien

Abstract

Although the philosophy of management of patients with chronic lymphocytic leukaemia (CLL) has been altered with the advent of fludarabine-based therapies, impact on long-term survival is unclear and a significant proportion of patients will develop resistance to fludarabine. Similar to other haematological malignancies, a potential for 'cure' is likely to be achieved only if 'high-quality' complete remissions (CRs) are achieved. Treatment options for patients who develop resistance to fludarabine continue to be limited, with only a proportion obtaining a response (usually not CRs) with salvage therapies. This review summarises novel therapies that are being evaluated in patients with CLL, specifically those targeting the antiapoptotic Bcl-2 family of proteins and receptors (e.g., CD40, CD80, HLA-DR) involved in mediating survival signals from the microenvironment.

References

Apr 1, 1992·The Journal of Clinical Investigation·S FournierM Sarfati
Jan 1, 1991·Advances in Immunology·G DelespesseA Dalloul
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Aug 1, 1994·The Journal of Experimental Medicine·K S HathcockR J Hodes
Jan 1, 1993·The Journal of Experimental Medicine·M BuschleM K Brenner
Feb 1, 1995·British Journal of Haematology·S FournierM Sarfati
Apr 1, 1995·Clinical Immunology and Immunopathology·F DazziF Caligaris-Cappio
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ReinischG Boltz-Nitulescu
Jun 1, 1994·International Immunology·J P TrumanN A Mooney
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M K NewellJ H Freed
Jan 1, 1994·The Journal of Experimental Medicine·A C FluckigerJ Banchereau
Jan 1, 1997·Annual Review of Immunology·T F TedderJ H Kehrl
May 1, 1997·British Journal of Haematology·D WangM J Robertson
Sep 1, 1997·Nature Medicine·M CantwellT J Kipps
May 23, 1998·Annual Review of Immunology·I S Grewal, R A Flavell
Jul 1, 1999·Bioorganic & Medicinal Chemistry Letters·G W MullerD I Stirling
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Caligaris-Cappio, T J Hamblin
Oct 16, 1999·Cytometry·K HanS M Kim
Feb 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·R R FurmanE J Schattner
May 17, 2000·The Journal of Experimental Medicine·M HaraguchiJ C Reed
Jun 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S J FaasR P Rother
Sep 7, 2000·The New England Journal of Medicine·J Klein, A Sato
Mar 13, 2001·Annual Review of Immunology·B Salomon, J A Bluestone
Apr 12, 2001·The Journal of Biological Chemistry·J A KeiferA S Baldwin
Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·S A KostelnyG J Weiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.